Literature DB >> 19292604

Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.

Piotr Hadaczek1, John Forsayeth, Hanna Mirek, Keith Munson, John Bringas, Phil Pivirotto, Jodi L McBride, Beverly L Davidson, Krystof S Bankiewicz.   

Abstract

We used convection-enhanced delivery (CED) to characterize gene delivery mediated by adeno-associated virus type 1 (AAV1) by tracking expression of hrGFP (humanized green fluorescent protein from Renilla reniformis) into the striatum, basal forebrain, and corona radiata of monkey brain. Four cynomolgus monkeys received single infusions into corona radiata, putamen, and caudate. The other group (n = 4) received infusions into basal forebrain. Thirty days after infusion animals were killed and their brains were processed for immunohistochemical evaluation. Volumetric analysis of GFP-positive brain areas was performed. AAV1-hrGFP infusions resulted in approximately 550, 700, and 73 mm(3) coverage after infusion into corona radiata, striatum, and basal forebrain, respectively. Aside from targeted regions, other brain structures also showed GFP signal (internal and external globus pallidus, subthalamic nucleus), supporting the idea that AAV1 is actively trafficked to regions distal from the infusion site. In addition to neuronal transduction, a significant nonneuronal cell population was transduced by AAV1 vector; for example, oligodendrocytes in corona radiata and astrocytes in the striatum. We observed a strong humoral and cell-mediated response against AAV1-hrGFP in transduced monkeys irrespective of the anatomic location of the infusion, as evidenced by induction of circulating anti-AAV1 and anti-hrGFP antibodies, as well as infiltration of CD4(+) lymphocytes and upregulation of MHC-II in regions infused with vector. We conclude that transduction of antigen-presenting cells within the CNS is a likely cause of this response and that caution is warranted when foreign transgenes are used as reporters in gene therapy studies with vectors with broader tropism than AAV2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19292604      PMCID: PMC2730589          DOI: 10.1089/hum.2008.151

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  46 in total

1.  Targeted retrograde gene delivery for neuronal protection.

Authors:  Brian K Kaspar; Dawn Erickson; David Schaffer; Linda Hinh; Fred H Gage; Daniel A Peterson
Journal:  Mol Ther       Date:  2002-01       Impact factor: 11.454

2.  Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion.

Authors:  Mihail Y Mastakov; Kristin Baer; Robert M Kotin; Matthew J During
Journal:  Mol Ther       Date:  2002-04       Impact factor: 11.454

3.  Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain.

Authors:  J B Nguyen; R Sanchez-Pernaute; J Cunningham; K S Bankiewicz
Journal:  Neuroreport       Date:  2001-07-03       Impact factor: 1.837

4.  Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

Authors:  K S Bankiewicz; J L Eberling; M Kohutnicka; W Jagust; P Pivirotto; J Bringas; J Cunningham; T F Budinger; J Harvey-White
Journal:  Exp Neurol       Date:  2000-07       Impact factor: 5.330

5.  Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors.

Authors:  C L Halbert; J M Allen; A D Miller
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Distribution of AAV-TK following intracranial convection-enhanced delivery into rats.

Authors:  J Cunningham; Y Oiwa; D Nagy; G Podsakoff; P Colosi; K S Bankiewicz
Journal:  Cell Transplant       Date:  2000 Sep-Oct       Impact factor: 4.064

7.  Role of astrocytes in antigen presentation and naive T-cell activation.

Authors:  A Cornet; E Bettelli; M Oukka; C Cambouris; V Avellana-Adalid; K Kosmatopoulos; R S Liblau
Journal:  J Neuroimmunol       Date:  2000-07-01       Impact factor: 3.478

8.  Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus.

Authors:  H Chen; D M McCarty; A T Bruce; K Suzuki
Journal:  J Neurosci Res       Date:  1999-02-15       Impact factor: 4.164

9.  Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Authors:  Katsuya Inagaki; Sally Fuess; Theresa A Storm; Gregory A Gibson; Charles F Mctiernan; Mark A Kay; Hiroyuki Nakai
Journal:  Mol Ther       Date:  2006-05-19       Impact factor: 11.454

10.  Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope.

Authors:  A Gambotto; G Dworacki; V Cicinnati; T Kenniston; J Steitz; T Tüting; P D Robbins; A B DeLeo
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

View more
  46 in total

1.  Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

Authors:  Piotr Hadaczek; Jamie L Eberling; Philip Pivirotto; John Bringas; John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  AAV provides an alternative for gene therapy of the peripheral sensory nervous system.

Authors:  Andreas S Beutler
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

3.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

Review 4.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 5.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 6.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.

Authors:  Lluis Samaranch; Ernesto A Salegio; Waldy San Sebastian; Adrian P Kells; Kevin D Foust; John R Bringas; Clementine Lamarre; John Forsayeth; Brian K Kaspar; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-03-28       Impact factor: 5.695

Review 8.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

9.  AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.

Authors:  Jonathan B Rosenberg; Michael G Kaplitt; Bishnu P De; Alvin Chen; Thomas Flagiello; Christiana Salami; Eduard Pey; Lingzhi Zhao; Rodolfo J Ricart Arbona; Sebastien Monette; Jonathan P Dyke; Douglas J Ballon; Stephen M Kaminsky; Dolan Sondhi; Gregory A Petsko; Steven M Paul; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2018-03-13       Impact factor: 5.032

10.  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.

Authors:  Hemraj B Dodiya; Tomas Bjorklund; James Stansell; Ronald J Mandel; Deniz Kirik; Jeffrey H Kordower
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.